"Human clinical trial for “First in Man” use of biopolymer scaffolding to treat acute SCI expected to commence in early 2013 under a Humanitarian Device Exemption (HDE) pathway, pending FDA approval of the related IDE application"
It will either happen or it won't. If the trial moves forward, the stock will recover lost ground. If it doesn't or there are delays requiring them to practice on some more monkeys, - then the stock tanks further and they'll most likely have to sell out on the cheap rather than go bankrupt....GLTA
The company was built as one would go about building a private corporation. It would be advantageous for a buyer to purchase it BEFORE it uplifted to Nasdaq so its a reasonable
assumption that the stock is being held down for that reason. IMHO